drugset / Trial / NCT05630885
A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV
Phase 2
Completed
110 enrolled
National Institute of Allergy and Infectious Diseases (NIAID)
AbbVie · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The study was conducted to determine if cenicriviroc mesylate (CVC) would decrease vascular inflammation as measured by 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) imaging of the aorta and carotid arteries.
Timeline
- Start
- 2023-05-30
- Primary completion
- 2024-06-19
- Completion
- 2024-06-19
Outcome
Missed primary endpoint
registry analysis (superiority test); CVC Arm (Arm A) vs Placebo for CVC Arm (Arm B); p = 0.65 NCT05630885 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cenicriviroc | Small molecule | 150 mg | Oral |
| Subject | Cenicriviroc | Small molecule | 300 mg | Oral |